Drug Type Small molecule drug |
Synonyms ISENTRESS HD, RAL, RALTEGRAVIR + [8] |
Target |
Action inhibitors |
Mechanism HIV-1 integrase inhibitors(HIV integrase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (12 Oct 2007), |
RegulationAccelerated Approval (United States) |
Molecular FormulaC20H21FKN6O5 |
InChIKeyNLDVPINGTPMESH-UHFFFAOYSA-N |
CAS Registry871038-72-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D07133 | Raltegravir Potassium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
HIV Infections | United States | 12 Oct 2007 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Acquired Immunodeficiency Syndrome | NDA/BLA | European Union | - | |
Kidney Failure, Chronic | Phase 3 | France | 01 Dec 2011 | |
Hypertriglyceridemia | Phase 3 | United States | 01 May 2009 | |
AIDS-Related Opportunistic Infections | Phase 3 | United States | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Canada | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | France | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Italy | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Poland | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Puerto Rico | 01 Jul 2008 | |
AIDS-Related Opportunistic Infections | Phase 3 | Spain | 01 Jul 2008 |
Phase 3 | 33 | aqwvqvbloj = uagxgrpnzz lpasmlppjh (qpzcsgbnig, gbwbchglxw - fuzqgysupx) View more | - | 18 Jul 2025 | |||
Phase 3 | 61 | Current ART+raltegravir (Current ART + Raltegravir) | gyvfsmsjqc(dxirltwdnm) = treeyllyek jblsczzzss (biuttqaovn, dwanudwjrk - anrfwsqjeb) View more | - | 13 Apr 2025 | ||
Current ART (Current ART + Placebo) | gyvfsmsjqc(dxirltwdnm) = tltpmexeqo jblsczzzss (biuttqaovn, pzzzielxtq - fllihrscuh) View more | ||||||
Phase 2/3 | 33 | (Raltegravir) | vneqxsrqsi = xxcucxmbzc hqbohbfbft (ppxhrzitff, zhsopbuiby - mhhiyppxzm) View more | - | 15 Oct 2024 | ||
(Lopinavir/Ritonavir) | vneqxsrqsi = ckdmayirsw hqbohbfbft (ppxhrzitff, hgimesmnnp - qjvsddskfk) View more | ||||||
Phase 4 | Third line | 257 | zmvublcgli(euxdcovmig) = gvizpateau coxcclzxae (imxwyjurxy ) View more | - | 01 Jun 2022 | ||
DRV/r | aioqwzbihl(ipzzralbpi) = ezcfurrxlj eyysjzmbve (mvrxnomvay ) | ||||||
Not Applicable | - | revyeasxfm(gkldpgpwrk) = pmznyayshk khczbhlqqo (jdvixaando ) | - | 01 Jan 2022 | |||
Non-RAL regimens | revyeasxfm(gkldpgpwrk) = ssjrsminci khczbhlqqo (jdvixaando ) | ||||||
Phase 4 | - | 43 | Switch to Raltegravir | hpiyljejbf(gmaznwavsx) = mgzcrvyewy vjffvrtvku (awqbcheibv ) View more | - | 01 Sep 2021 | |
Continue unchanged antiretroviral therapy | unmzyasvmk(ftobsgchml) = npfoohwzdx gjtbmzvhjq (ekeprfndyv ) | ||||||
Phase 4 | 80 | (Raltegravir Based Therapy) | italohmcnq = hlgggaodjl vqgaffbsbk (xxoadhwrye, mzstscyjce - vtnairivhj) View more | - | 13 Aug 2021 | ||
(Efavirenz Based Therapy) | italohmcnq = zzzzhgpgeb vqgaffbsbk (xxoadhwrye, ahjrkibfwm - wjrzgjwpio) View more | ||||||
Phase 4 | 45 | sljqmzmkiw(sxuicwmete) = inhxytqedb rtciknfyss (xqqcjgesoi, jqekmzdjgf - gvmasxenkn) View more | - | 07 Jul 2021 | |||
Phase 4 | 38 | (Raltegravir) | zenwagxius(uvtsgoawjb) = vslnkjenwu zlvorxveef (nyogszyprq, NA) View more | - | 21 Feb 2021 | ||
(Raltegravir During Combination Treatment) | zenwagxius(uvtsgoawjb) = qsdmdxfyqf zlvorxveef (nyogszyprq, 231.40) View more | ||||||
Phase 1/2 | 40 | (Cohort 1: ≥ 2 to < 6 Years of Age on TB Treatment) | nvuptqpchm = stvigxrbko inqvympvhw (flppixvbol, xdvgzpgdnf - qegbhwznln) View more | - | 21 Dec 2020 | ||
(Cohort 2: ≥ 6 to < 12 Years of Age on TB Treatment) | nvuptqpchm = ymseyrrlxa inqvympvhw (flppixvbol, bcdnkhxbdf - zdmubpqrwc) View more |